Instalab
logoInstalab

Omega Gliadin IgA

Blood Test
Explore whether your immune system is reacting to wheat gluten, a possible early clue toward celiac disease.
4.9 (4,901 reviews)
Tested by Vibrant America
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Omega Gliadin IgA test?

This test is most useful if any of these apply to you.

Celiac Runs in Your Family
A close relative with celiac disease raises your own odds, and this adds one more antibody clue to a gluten workup.
Living With Another Autoimmune Condition
Type 1 diabetes and autoimmune thyroid disease overlap with celiac, so a gluten antibody check can catch a hidden connection.
Chasing Unexplained Gut or Iron Problems
Chronic diarrhea, bloating, or stubborn iron deficiency can trace back to gluten, and this helps round out the picture.
Healthy but Curious About Gluten
If your standard labs look normal but you wonder whether gluten bothers you, this offers an extra, exploratory read.

About Omega Gliadin IgA

If you suspect gluten is a problem for you, this is one of the antibody signals your blood can carry. It reflects whether your immune system is producing antibodies aimed at a specific protein in wheat, and in the right context it can point toward celiac disease. On its own, though, it does not diagnose anything.

This is not the first test a clinician reaches for. Modern celiac screening leans on a different antibody, and this one plays a smaller, supporting role. In fact, current guidelines recommend against using older native gliadin antibody tests to evaluate for celiac disease, so knowing what this marker does and does not tell you is what makes a result useful rather than confusing.

What Omega-Gliadin IgA Actually Measures

Gluten in wheat is made of several related proteins called gliadins, grouped into families named alpha, beta, gamma, and omega. This test measures omega-gliadin IgA, meaning immunoglobulin A (a class of antibody your body makes, especially in the gut lining) aimed specifically at the omega-gliadin family. The lab measures the concentration of that antibody in your blood, which reflects how strongly your immune system is targeting this one wheat protein.

In people with celiac disease, the IgA response to gluten often narrows down onto omega-gliadins. In the one study that looked at this marker directly, serum IgA showed intense reactivity against omega-gliadins in 15 of 23 celiac patients, and in 7 of those patients the IgA reacted to omega-gliadins alone. That pattern suggests omega-gliadin can capture a focused part of the gluten-directed immune response.

The Celiac Disease Connection

The clearest reason to care about this marker is celiac disease, an immune reaction to gluten that damages the small intestine. In that same study, an assay built on the omega-gliadin fraction produced the best overall performance among the gliadin proteins tested, with the fewest false positives and false negatives.

It also lined up well with a trusted celiac antibody test. Results for omega-gliadin IgA agreed with endomysial antibody testing, matching in 26 of 28 biopsy-confirmed celiac cases. That kind of agreement is why the marker is considered supportive of celiac serology, even though it comes from a single older study with modest numbers.

How It Stacks Up Against the Standard Celiac Test

The best-supported first-line blood test for celiac disease is tissue transglutaminase IgA (tTG-IgA, an antibody against one of your own gut enzymes), paired with a total IgA measurement. Gliadin-based IgA tests generally do not beat it, and guidelines specifically advise against relying on older native gliadin antibody tests. The table below uses evidence from closely related gliadin and deamidated gliadin peptide antibodies, since head-to-head data on omega-gliadin IgA specifically is limited.

Who Was StudiedWhat Was ComparedWhat They Found
Adults with suspected celiac diseaseOlder gliadin IgA vs deamidated gliadin IgAThe deamidated version caught about 74 out of 100 cases versus about 63 for the older gliadin test, and was more accurate overall
Adults with suspected celiac diseaseGliadin peptide IgA vs tTG-IgASimilar case detection, but tTG-IgA correctly cleared slightly more people without celiac (about 98 vs 95 out of 100)
Studies pooled togetherGliadin peptide antibodies vs tTG antibodiestTG caught about 93 out of 100 cases versus about 88 for gliadin peptide, so tTG remained the preferred screen

Source: Rashtak et al. 2008; Lewis and Scott 2010.

What this means for you: treat a gliadin-family IgA result as a helpful side note, not the headline. If celiac disease is the real question, a tTG-IgA plus total IgA is the number that carries the most weight, and this marker adds context rather than replacing it.

Not the Same as the Wheat Allergy Test

A common point of confusion is the omega-5 gliadin test used for wheat allergy. That test measures a different antibody class, IgE, and is used for immediate allergic reactions, including a condition where wheat plus exercise triggers anaphylaxis. Reported sensitivity varies widely by population, roughly 72 to 91 out of 100 cases caught for wheat allergy depending on the group studied and the cutoff used.

Omega-gliadin IgA is not that test. IgA reflects a slower, celiac-type immune reaction, while omega-5 gliadin IgE reflects an allergy that can cause hives or breathing trouble within minutes. A normal result on one tells you nothing reliable about the other, because they measure different immune systems responding to different aspects of wheat.

When a Single Reading Can Fool You

A few things can push this result in the wrong direction and lead you to a false conclusion:

  • Being off gluten: gliadin antibodies fall when you stop eating gluten, so a gluten-free diet at the time of testing can make the result look reassuringly low even if you have celiac disease.
  • Low total IgA: some people do not make much IgA at all, and in that case any IgA-based antibody test can read low or negative despite real celiac disease, which is why a total IgA and IgG-based tests are used as backup.
  • An isolated positive with normal tTG-IgA: a lone positive gliadin-family result when tTG-IgA is normal rarely means celiac disease, with a positive predictive value around 2.5 percent in one study of children.
  • Assay differences: native gliadin, deamidated gliadin peptide, and omega-gliadin assays are not identical, so results and cutoffs vary between labs.

Why Trends Beat One-Off Numbers

Antibody levels are not fixed. They rise and fall with gluten exposure over weeks to months, so a single value is a snapshot of a moving target. That is exactly why tracking is more informative than any one reading, especially if you are making a dietary change.

For someone diagnosed with celiac disease who goes gluten-free, gliadin-family antibodies fall as the gut heals, and falling levels have been used to gauge how strictly gluten is being avoided. That long-term tracking evidence comes from related gliadin and deamidated gliadin peptide antibodies rather than omega-gliadin IgA measured over time, so read this as the general behavior of the antibody family. A reasonable rhythm is a baseline while you are still eating gluten, then a follow-up around 6 to 12 months into a gluten-free diet, and periodic checks after that.

What to Do With an Unexpected Result

A high result is a prompt to build a fuller picture, not a diagnosis. The most useful next step is to confirm with tTG-IgA and a total IgA measurement, since those anchor the standard celiac workup. If tTG-IgA is also elevated, that combination is worth bringing to a gastroenterologist, who may discuss a duodenal biopsy or a no-biopsy pathway.

If this marker is positive but tTG-IgA is normal, ask two questions first: were you eating gluten when tested, and is your total IgA low. Both can explain a mismatch. Genetic testing for the celiac risk genes HLA-DQ2 and HLA-DQ8 can also help, because their absence makes celiac disease very unlikely. The one thing not to do is cut out gluten before testing is complete, since that can erase the very antibodies the workup depends on.

What Moves This Biomarker

Evidence-backed interventions that affect your Omega Gliadin IgA level

Decrease
Follow a strict gluten-free diet
Removing gluten takes away the trigger, and gliadin-family antibodies fall over months as the gut heals. The direct long-term tracking evidence here comes from related gliadin and deamidated gliadin peptide antibodies rather than omega-gliadin IgA specifically, where declining levels tracked recovery of the intestinal lining and were used to judge how strictly gluten was being avoided. For diagnosed celiac disease, a gluten-free diet is the core treatment, so a falling antibody level is the goal, not a warning.
DietStrong Evidence
Increase
Eat a gluten-containing diet
Your body only makes gliadin antibodies, including omega-gliadin IgA, when it is actually exposed to wheat gluten. In the one study measuring this marker, celiac patients who were eating gluten showed intense omega-gliadin IgA reactivity in 15 of 23 cases, and 7 of 23 reacted to omega-gliadins alone. If you have celiac disease, this ongoing immune response reflects continued injury to the intestinal lining, which is why gluten is not harmless in that setting. It also means you need to stay on gluten before testing, or the result can read falsely low.
DietModerate Evidence

Frequently Asked Questions

Panels containing Omega Gliadin IgA

Omega Gliadin IgA is included in these pre-built panels.

References

15 studies
  1. Chirdo F, Rumbo M, Carabajal P, Castagnino N, Mavromatopulos E, Cirincione V, Añón MC, Fossati CAJournal of Pediatric Gastroenterology and Nutrition1999
  2. Husby S, Koletzko S, Korponay-szabó I, Kurppa K, Mearin M, Ribes-koninckx C, Shamir R, Troncone RJournal of Pediatric Gastroenterology & Nutrition2020
  3. Rashtak S, Ettore MW, Homburger H, Murray JClinical Gastroenterology and Hepatology2008
  4. Villalta D, Tonutti E, Prause C, Koletzko S, Uhlig H, Vermeersch P, Bossuyt X, Stern MClinical Chemistry2010